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Abstract 
Lung cancer is still the leading cause of death among all cancers. During the last 15 years, pharmacogenomics of lung 
cancer have established targeted therapy with tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor 
(EGFR) positive patients in adenocarcinoma or mixed adenosquamus lung cancer patients. However; while novel 
drugs are released in the market, at the same time novel mutations are observed after tyrosine kinase inhibitor admin‑
istration. Recently the novel mutation T790 was observed and is highly prevalent in patients already treated with a 
TKI. A new drug targeting this mutation is already on the market, however; the most important factor for successful 
treatment in these patients, is adequate tissue re‑sampling so that novel mutations can be detected.
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Background
Lung cancer is still diagnosed at a late stage disease, 
mainly due to the lack of early disease symptoms and 
the absence of an effective screening strategy. Therefore 
most patients are diagnosed at a non-operable stage and 
systematic treatment has to be administered. Nowadays, 
non-small cell lung cancer (NSCLC) treatment includes 
non-specific cytotoxic agents in the form of chemother-
apy and anti-vascular endothelial growth factors. More-
over, in the last 15  years, pharmacogenomics as well as 
focused research in adenocarcinoma resulted in targeted 
treatments for epidermal growth factor receptor (EGFR) 
and anaplastic lymphoma kinase positive patients (ALK). 
These two groups of patients are currently candidates 
for oral kinase inhibitors in the form of a capsule. Now-
adays we have already have 1st, 2nd and 3rd generation 
TKIs as well as ALK inhibitors in the market [1–3]. Right 
now ROS1 pathway can be inhibited with crizotinib. 
Moreover; immunotherapy has just been established for 
NSCLC, although several drugs were already on the mar-
ket for other malignancies such as melanoma [4].
Main Text
In order to diagnose and molecularly characterize lung 
cancer, adequate tissue sampling is paramount and sev-
eral techniques are being used such as; bronchoscopy, 
endobronchial ultrasound (radial–linear), biopsy under 
CT guidance, or even surgery. In everyday practice, most 
of these procedures are performed by interventional pul-
monary physicians, while radiologists and thoracic sur-
geons are also involved in tissue sampling when required. 
Current biopsy techniques acquire cytology samples 
and tissue biopsies, or even cytological sample with tis-
sue fragments. The sample depends on the biopsy equip-
ment and the technique that the physician is using. Most 
centers and physicians use the equipment that they have 
available with the technique that is safer for the patient. 
The sample is then forwarded to the cytology or pathol-
ogy laboratory for diagnosis. However; we should keep in 
mind that for several biopsy techniques more advanced 
sample diagnostic procedures such as cell blocks have 
to be utilized [5]. So, one of the issues that have to be 
resolved before any biopsy procedure, is the proper 
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handling of the acquired sample. After confirmation 
of diagnosis, both cytology or histology samples can be 
used for molecular testing in order to investigate EGFR, 
ALK, KRAS, ROS1, BRAF and MET mutations. Molecu-
lar testing is usually performed for EGFR and ALK muta-
tions but other markers such as KRAS, ROS1, BRAF and 
MET mutations can be tested and, within clinical stud-
ies, medications are available [6–8]. However, these other 
treatments have not been approved for use in lung can-
cer. And, in all cases, enough tissue should be sampled so 
that the diagnosis is accurate and molecular testing can 
be performed. Although, there are diagnostic platforms 
who can investigate EGFR mutations using just 3 cells, 
this does not allow the investigation of other molecular 
pathway over-expressions [9]. Currently molecular biolo-
gists along with pharmaceutical companies have estab-
lished liquid biopsy techniques [10]. Although; these 
techniques still have a lower yield they could be used in 
those patients where re-biopsy is not possible due to per-
formance status [11]. It must be taken into account that a 
positive liquid biopsy result is considered acceptable for 
diagnosis, however, a negative result does not rule out 
positivity of the lung cancer tumor cells or at the site of 
metastases.
So tissue is the issue: research into lung cancer treat-
ment is booming and is leading to the rapid development 
of new medications. As more targeted treatment options 
become available, testing for multiple markers is required 
and abundant, good quality samples need to be acquired 
[12]. Moreover, we have come to understand that lung 
cancer cells mutate and change throughout treatment 
and therefore the molecular characterization of these tis-
sue samples acquired both at diagnosis and at relapse is 
pivotal in guiding treatment decisions second line treat-
ment and beyond second line.
Discussion
As an example of the research and evolution in lung can-
cer, within 10 years of the first TKI use in clinical prac-
tice, a new mutation appeared in far higher proportions 
in treated patients, T790, a mutation that makes them 
non-responsive to first and second generation TKIs [13]. 
A novel TKI was developed and is already on the mar-
ket, ossimertinib, AZD9291 [14]. It is therefore impera-
tive to re-examine and re-biopsy the patients with disease 
relapse under anti-EGFR-TKI [15]. Major issues for these 
patients are where to perform the re-biopsy and whether 
the patient is fit for re-biopsy. In cases where the patient 
is not fit for re-biopsy, liquid biopsy is an option. In the 
study by Oxnard et  al. [16] data presented that, upon 
availability of validated plasma T790M assays, some 
patients could avoid a tumor biopsy for T790M genotyp-
ing. As a result of the 30% false-negative rate of plasma 
genotyping, those with T790M-negative plasma results 
still need a tumor biopsy to determine presence or 
absence of T790M. Moreover; this not invasive method 
could be used during the follow up of the patient muta-
tion status. However, where re-biopsy is possible, current 
clinical practice indicates that re-biopsy has to be per-
formed at the site where relapse was observed, whether 
the primary site, a lymph node or a distant metastasis 
such as in the liver and, where the necessary equipment 
or experience is not adequate then the patient has to be 
referred to an experienced tertiary hospital. Perform-
ing re-biopsy at the site of relapse increases the rate of 
acquiring tissue harboring the novel mutation T790 and 
allows the patient a new chance for treatment. Finally, it 
should be stressed that fresh samples are always prefera-
ble in order to perform molecular testing. Tissue samples 
kept even under the best conditions in paraffin blocks, 
will still degrade the sample microenvironment so new 
biopsies are always advisable for the molecular character-
ization of the lung cancer in cases of relapse and before 
any changes in treatment decisions. Therefore probably 
re-biopsy should be proposed when necessary to the 
patient.
Conclusion
There has been an effort for non-interventional methods 
to investigate the status of T790, however; these efforts 
are still in initial stages [17]. Biopsy samples are still 
necessary and every effort has to be made towards early 
diagnosis and targeted treatment.
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